Purpose: Quality of life is a critical aspect in the management of older head and neck cancer patients. It needs to be considered alongside survival benefit, treatment burden, and longer-term outcomes. The purpose was to undertake a systematic review of empirical peer-reviewed studies with a primary focus on factors impacting quality of life for older head and neck cancer patients.
Methods: A systematic review, searching 5 electronic databases (PsychoINFO, MEDLINE, CINHAL, Embase, and Scopus) using PRISMA methodology was conducted. Data was appraised using the Newcastle-Ottawa scale and a narrative synthesis performed.
Results: Only 10 papers fulfilled the inclusion criteria. Two main themes emerged: 1) Impact of head and neck cancer on quality of life domains and 2) quality of life in treatment decision-making.
Conclusions: In an era of progressive personalised care, there is an evident need for more qualitative and quantitative studies focusing on quality of life for older head and neck cancer patients. However, older head and neck cancer patients experience notable differences, especially with poorer physical functioning and greater eating and drinking challenges. Quality of life impacts older patients decision-making, treatment planning and intensifies post-treatment support.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejon.2023.102280 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pulmonary arterial hypertension (PAH) is a chronic progressive exacerbation of cardiopulmonary vascular disease. The patients' exercise endurance decreased progressively and the survival rate was low. Current basic therapy and targeted drug therapy can improve the quality of life (QoL) of PAH patients, but the long-term efficacy and prognosis are not good.
View Article and Find Full Text PDFDevelopment of a Transcultural Social Ethical and Integrated Care Model, for Dependent and Older People Populations at Risk of Exclusion in the Mediterranean Sea Basin (TEC-MED): A Research Protocol.
Int J Integr Care
December 2024
Departamento de Enfermería, Facultad de Enfermería, Fisioterapia y Podología, Universidad de Sevilla, Spain.
Background: Higher life expectancy has produced a higher older people porpulation, not necessarily with a consistent quality of life, showing a high rate of vulnerability and dependence. The current social and health crisis situation has highlighted the need to create new integrated models of care that could be translated into social and health policies.
Objective: The present study aims to develop, test, and validate an innovative integrated care model for older people with dependence and at risk of social exclusion and their caregivers.
Cost-effectiveness of camrelizumab plus rivoceranib for advanced hepatocellular carcinoma in the context of regional disparities in China.
Front Oncol
December 2024
Department of Oncology, Binzhou Medical University Hospital, Binzhou, Shandong, China.
Objective: To assess the cost-effectiveness of combining camrelizumab with rivoceranib versus sorafenib as initial treatment options for advanced hepatocellular carcinoma (HCC) across different developmental regions in China.
Methods: Utilizing TreeAge Pro and data from the phase III randomized CARES-310 clinical trial, a model based on Markov state transitions was developed. Health state utility values were derived from the CARES-310 trial, and direct medical costs were obtained from relevant literature and local pricing data.
The Efficacy and Safety of Radio Electric Asymmetric Conveyer (REAC) External Radio Electric Reprogramming for Atrial Fibrillation (EX-RER AF) Treatment: Results From a Post-market Clinical Follow-Up.
Cureus
December 2024
Department of Regenerative Medicine, Rinaldi Fontani Institute, Florence, ITA.
This post-market clinical follow-up (PMCF) study evaluates the clinical effectiveness and safety of the external radio electric reprogramming for atrial fibrillation (EX-RER AF) protocol, a non-invasive regenerative medicine approach utilizing radio electric asymmetric conveyer (REAC) technology for managing paroxysmal atrial fibrillation (PAF). Administered with the REAC BENE mod 110 device (ASMED, Scandicci, Italy), the treatment involves a standardized procedure, with the asymmetric conveyor probe (ACP) positioned in the precordial area and fixed, unmodifiable parameters ensuring consistency and reproducibility. During a 36-month post-market clinical follow-up (PMCF), 20 patients with prior diagnoses of PAF underwent the protocol.
View Article and Find Full Text PDFDevelopment and implementation of a new part-time continuing education course in integrative oncology.
GMS J Med Educ
November 2024
Universitätsklinikum Jena, Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Jena, Germany.
Introduction: Integrative oncology combines evidence-based methods of oncological therapy, supportive medicine, nutrition and physical activity as well as complementary medicine and can significantly improve the effectiveness of therapy and the quality of life for cancer patients. However, scientifically based continuing education in this area has so far rarely been available.
Project Outline: The part-time continuing education program in "Integrative Onkologie" at the University of Jena is the first in Germany to offer scientifically based training for various healthcare professions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!